Skip to content
Screener

Zevra Therapeutics, Inc. ZVRA Business Segments — Income Tax Expense (Benefit)

Similar metrics at other companies

APO
APOGReportable Segment — Income Tax Expense (Benefit)
$4.4M-13.6%
Mama's Creations, Inc. logo
MAMAReportable Segment — Income Tax Expense (Benefit)
$577K+106%
Rimini Street, Inc. logo
RMNIReportable Segment — Income Tax Expense (Benefit)
$949K-77.7%
Krystal Biotech, Inc. logo
KRYSReportable Segment — Income Tax Expense (Benefit)
$5.51M-29.9%
ImmunityBio, Inc. logo
IBRXReportable Segment — Income Tax Expense (Benefit)
$9K+104%
Global Business Travel Group logo
GBTGReportable Segment — Income Tax Expense (Benefit)
$10M-39.4%

Other financials

Income statement

See full
Revenue$39.7M+53.3%
Gross profit$38.1M+182%
Operating income$16.8M+124%
Net income$8.8M-88.3%
EPS (diluted)$0.14-88.4%

Balance sheet

See full
Cash & equivalents$145.3M+205%
Total debt$1.5M-97.6%
Total equity$217.7M+85.7%
Total assets$302.7M+18.1%

Cash flow

See full
Operating cash flow$17.0M+573%
CapEx$217.0K+1.9%
Free cash flow$16.8M+541%

Valuation

See full
Market cap$705.48M+7.3%
Enterprise value$561.65M-17.1%
P/E12.1×-237×
P/S5.2×-5.4×

Profitability

See full
Gross margin95.5%+23.5pp
Operating margin-103.9%-43.0pp
Net margin42.8%+38.6pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity34.8%+31.3pp
Debt / equity-0.5×
Current ratio5.2×-2.7×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.

The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001434647-26-000068
Line itemThree months ended June 30, 2026Three months ended June 30, 2025Six months ended June 30, 2026Six months ended June 30, 2025
Selling, general and administrative not directly identified to programs13,42714,34327,77826,327
Other segment items:
Impairment of intangible assets58,71058,710
Income tax expense4,0422,19910,9573,381
Interest income(1,477)(2,257)(3,661)(2,975)
Depreciation and amortization expense3161,6517323,300
Interest expense2,0091,7113,978
Other income, net (a)6,985(135,353)(26,718)(138,738)

ITEM 1.FINANCIAL STATEMENTS

FAQ

What is Zevra Therapeutics, Inc.'s business segments — income tax expense (benefit)?
Zevra Therapeutics, Inc. (ZVRA) reported business segments — income tax expense (benefit) of $4.04M in Q2 2026.
How has Zevra Therapeutics, Inc.'s business segments — income tax expense (benefit) changed year-over-year?
Zevra Therapeutics, Inc.'s business segments — income tax expense (benefit) increased by 83.8% year-over-year, from $2.2M to $4.04M.
What does business segments — income tax expense (benefit) mean?
Reflects the provision for income taxes or tax benefits attributable to the segment's financial performance. It provides insight into the tax impact on the segment's bottom line and the company's overall effective tax rate.

Ask your AI about Zevra Therapeutics, Inc.'s business segments — income tax expense (benefit).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude